No 'wearing-off effect' seen with fremanezumab in the real-world: a retrospective, claims-based analysis of migraine-related healthcare resource and acute medication use

被引：0
|
作者：
Ailani, J. [1 ]
Xie, H. [2 ]
Driessen, M. [3 ]
Ortega, M. [4 ]
Wang, Y. [2 ]
Ramirez, Campos, V [2 ]
Lim, S. [2 ]
机构：
[1] MedStar Georgetown Univ Hosp, Washington, DC USA
[2] Teva Branded Pharmaceut Prod R&D Inc, W Chester, PA USA
[3] Teva Pharmaceut Ind Ltd, Amsterdam, Netherlands
[4] Teva Pharmaceut, Parsippany, NJ USA
来源：
HEADACHE | 2023年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-130
引用
收藏
页码：148 / 148
页数：1
相关论文
共 48 条
  • [41] Real-World Persistence and Costs Among Patients With Chronic Migraine Treated With OnabotulinumtoxinA or Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Claims Analysis Study
    Schwedt, Todd J.
    Lee, Jae
    Knievel, Kerry
    McVige, Jennifer
    Wang, Weiying
    Wu, Zheng
    Gillard, Patrick
    Shah, Darshini
    Blumenfeld, Andrew M.
    TOXICON, 2022, 214 : S68 - S69
  • [42] Real-world mepolizumab treatment in patients with severe asthma decreased exacerbations, oral corticosteroid use, and healthcare resource utilization and costs over 4 years: a retrospective analysis
    Moore, Wendy C.
    Stach-Klysh, Alexandra
    Corbridge, Thomas
    Packnett, Elizabeth
    Mcmorrow, Donna
    Richards, Megan
    Deb, Arijita
    JOURNAL OF ASTHMA, 2025,
  • [43] Real-World Treatment of Patients with Multiple Sclerosis per MS Subtype and Associated Healthcare Resource Use: An Analysis Based on 13,333 Patients in Germany
    Mueller, Sabrina
    Heidler, Tobias
    Fuchs, Andreas
    Pfaff, Andreas
    Ernst, Kathrin
    Ladinek, Gunter
    Wilke, Thomas
    NEUROLOGY AND THERAPY, 2020, 9 (01) : 67 - 83
  • [44] Real-World Treatment of Patients with Multiple Sclerosis per MS Subtype and Associated Healthcare Resource Use: An Analysis Based on 13,333 Patients in Germany
    Sabrina Müller
    Tobias Heidler
    Andreas Fuchs
    Andreas Pfaff
    Kathrin Ernst
    Gunter Ladinek
    Thomas Wilke
    Neurology and Therapy, 2020, 9 : 67 - 83
  • [45] Use of inpatient systemic chemotherapy and/or radiotherapy and related predictive factors, healthcare resource utilization, and direct hospitalization costs for metastatic urothelial cancer: findings from a real-world retrospective observational study derived from the national hospital discharge claims database in Italy
    Kearney, Mairead
    Kirker, Melissa
    Thompson, Allison
    Gharibian, Norbek
    Furegato, Martina
    Pacheco, Cecile
    Issa, Seham
    Hasanova, Reyhan
    Sciattella, Paolo
    Scortichini, Matteo
    Mennini, Francesco Saverio
    BMC CANCER, 2024, 24 (01)
  • [46] Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis
    Raju, Aditya
    Pimple, Pratik
    Stafkey-Mailey, Dana
    Farrelly, Eileen
    Shetty, Sharash
    DIABETES THERAPY, 2022, 13 (01) : 25 - 42
  • [47] Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis
    Aditya Raju
    Pratik Pimple
    Dana Stafkey-Mailey
    Eileen Farrelly
    Sharash Shetty
    Diabetes Therapy, 2022, 13 : 25 - 42
  • [48] Healthcare Resource Utilization and Associated Costs in New Users of Empagliflozin versus DPP-4 Inhibitors and GLP-I Agonists: A Comparative Analysis Based on Retrospective Real-World Data from German Sickness Funds
    Wilke, Thomas
    Picker, Nils
    Mueller, Sabrina
    Stuermlinger, Anna
    Deiters, Barthold
    Dittmar, Axel
    Aberle, Jens
    Gabler, Maximilian
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2022, 14 : 319 - 332
12345